Is a complete KROS research report available?

No complete published report is available for Keros Therapeutics, Inc. (KROS) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Keros Therapeutics, Inc. (KROS)

NASDAQ: KROS · USD

$10.1

-0.08 (-0.8%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-27 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first KROS analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	199.1M
Revenue (ttm)	33.2M
Net income (ttm)	-85.1M
EPS (ttm)	-$2.66
Shares out	19.8M
Volume	140,634
Beta	0.97
Price target	$21.8	+117.0%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 33.2M
Net income (ttm): -85.1M
EPS (ttm): -$2.66
Market cap: 199.1M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All KROS indicators

Market & fundamental data

Available fields

201

Groups with data

Currency

USD

Showing 201 of 201 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001664710
Company name	Keros Therapeutics, Inc.
Country	United States
Country code	US
Cusip	492327101
Employees	87
Employees Change	9%
Employees Change Percent	11.54
Enterprise value	$-66.1M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-04-08
Isin	US4923271013
Last refreshed	2026-07-27
Market cap	$199.1M
Market cap category	Micro-Cap
Price	$10.06
Price currency	USD
Rev Per Employee	381,402.3x
Sector	Healthcare
Sector PE	44.88
Sector PE Fwd	23.79
Sic	2834
Symbol	KROS
Website	https://www.kerostx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-42.76%
FCF yield	-29.26%
P/B ratio	0.7x
P/S ratio	6x
PS Forward	61.94x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-244.34%
EBITDA Margin	-239.62%
Gross margin	-184.89%
Gross Profit	$-61.3M
Net Income	$-85.1M
Net Income Growth Years	1%
Pretax Margin	-272.15%
Profit Margin	-256.6%
Profit Per Employee	$-978,678
Profitable Years	1
ROA	-12.23
Roa5y	-17.57
ROCE	-27.08
ROE	-16.79
Roe5y	-27.05
ROIC	-404.8
Roic5y	-774.4

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-30.3%
Cagr3y	-38.38%
Cagr5y	-23.24%
EPS Growth Years	2
Revenue Growth	-84.55x
Revenue Growth Q	-99.83x
Revenue Growth Years	2x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.06
Assets	$312.3M
Cash	$281.5M
Current Assets	$290.7M
Current Liabilities	$12.9M
Debt	$16.3M
Debt Equity	$0.06
Equity	$285.6M
Liabilities	$26.7M
Long Term Assets	$21.6M
Long Term Liabilities	$13.8M
Net Cash	$265.2M
Net Cash By Market Cap	$133
Net Cash Growth	-62.23%
Net Debt Equity	$-0.93
Tangible Book Value	$285.6M
Tangible Book Value Per Share	$14.47
WACC	8.86

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	22.62
Net Working Capital	$-1.2M
Quick ratio	22.17
Working Capital	$277.8M
Working Capital Turnover	$0.07

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	17.49%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-30.28%
200-day SMA	14.39
3Y total return	-76.62%
50-day SMA	10.77
50-day SMA vs 200-day SMA	50under200
5Y total return	-73.35%
All Time High	88.8
All Time High Change	-88.67%
All Time High Date	2020-12-08
All Time Low	9.12
All Time Low Change	10.31%
All Time Low Date	2025-04-09
ATR	0.52
Beta	0.97
Beta1y	1.34
Beta2y	1.04
Ch YTD	-50.59
High	10.36
High52	22.55
High52 Date	2025-12-08
High52ch	-55.39%
Low	10.02
Low52	9.69
Low52 Date	2026-06-11
Low52ch	3.82%
Ma50ch	-6.58%
Price vs 200-day SMA	-30.11%
RSI	39.16
RSI Monthly	36.13
RSI Weekly	36.7
Sharpe ratio	-0.58x
Sortino ratio	-0.68
Total Return	17.49%
Tr YTD	-50.59
Tr1m	-8.55%
Tr1w	-5.45%
Tr3m	-12.98%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	7
Analyst Count Top	4
Analyst Price Target Top	$20
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-1.24
Earnings Revenue Estimate	635,000x
Earnings Revenue Estimate Growth	-96.5x
Operating Income	$-107.3M
Operating margin	-323.5
Price target	$21.83
Price Target Change	$117
Price Target Change Top	$98.81

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	17,797,399%
Float Percent	89.92%
Shares Insiders	3.2%
Shares Institutions	89.69%
Shares Out	19,791,837
Shares Qo Q	-27.83%
Shares Yo Y	-17.49%
Short Float	5.95%
Short Ratio	3.16
Short Shares	5.35

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-84.3M
Average Volume	297,009.8x
Bv Per Share	14.47
CAPEX	$-1.1M
Ch1m	-8.55
Ch1w	-5.45
Ch1y	-30.28
Ch3m	-12.98
Ch3y	-76.62
Ch5y	-73.35
Ch6m	-47.6
Change	-0.79%
Change From Open	-2.9
Close	10.14
Days Gap	2.17
Depreciation Amortization	1,568,000
Dollar Volume	1,414,778
Earnings Date	2026-08-14
Earnings Time	amc
EBIT	$-81.1M
EBITDA	$-79.5M
EPS	$-2.66
F Score	2
FCF	$-58.3M
FCF EV Yield	88.16x
FCF Per Share	$-2.94
Financing CF	-380,790,000
Fiscal Year End	December
Founded	2,015
Income Tax	$-5.2M
Investing CF	-1,059,000
Ipr	-37.13
Iprfo	-51.75
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-14
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-04
Ma150	13.51
Ma150ch	-25.52%
Ma20	10.92
Ma20ch	-7.91%
Net CF	-439,044,000
Next Earnings Date	2026-08-05
Open	10.36
Optionable	Yes
Position In Range	11.76
Ppne	20,167,000
Price Date	2026-07-24
Ptbv Ratio	0.7
Relative Volume	0.47x
Revenue	33,182,000x
SBC By Revenue	78.45x
Share Based Comp	26,032,000
Tax By Revenue	-15.55x
Tr6m	-47.6%
Us State	Massachusetts
Volume	140,634
Z Score	9.87

Keros Therapeutics, Inc. (KROS)

Coverage state: Market snapshot only — no published research

Generate the first KROS analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · KROS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All KROS indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on KROS

Frequently asked questions